Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lu 177 edotreotide - ITM Solucin

Next Previous
Drug Profile

Lu 177 edotreotide - ITM Solucin

Alternative Names: 177Lu-DOTATOC; 177Lu-Edo; 177Lu-edotreotide; 177Lu-edotreotide PRRT; DP-1111; ITM-11; Lutetium 177 Edotreotide; Lutetium-177 labelled edotreotide - ITM Solucin; n.c.a.177Lu DOTATOC; n.c.a.177Lu-Edotreotide; Peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide; Solucin; Targeted Radionuclide Therapy with 177Lu-edotreotide

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ITM Solucin
  • Class Antineoplastics; Drug conjugates; Peptide drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuroendocrine tumours
  • Preclinical Cancer

Most Recent Events

  • 13 Jun 2025 ITM Solucin completes the phase III COMPETE trial for Neuroendocrine tumours in Austria, Australia, Belgium, Czech Republic, Germany, Switzerland, South Africa, the United Kingdom, France, Italy, Netherlands, Spain, Poland, and USA (IV) (NCT03049189)
  • 06 Mar 2025 Updated efficacy and adverse event data from the phase II COMPETE trial in Neuroendocrine tumours released by ITM Medical Isotopes GmbH
  • 28 Jan 2025 ITM announces intention to submit NDA to the US FDA for Neuroendocrine tumours in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top